Index

A2 genotype 137
A24 genotype 137
A29 genotype 137
A*3101 genotype 137
A*6801 genotype 137
A/B classification 32–4
ABCB1 (MDR1) gene 131
ABCC1 gene 131
ABCC2 gene 131
ABCG2 gene 131
abacavir 93, 136–7, 142–5, 191, 403
absorption interactions 56
abuse of medicinal products 472, 518
ACE inhibitors see angiotensin converting enzyme inhibitors
acetaminophen see paracetamol
acetylcholinesterase 134
ACHE gene 134
adrenaline 49
adrenoceptor antagonists 45
adulterants 39, 665
adverse drug experiences 90, 497–8
adverse drug reaction dictionaries 551–4
Adverse Drug Reactions On-Line Information Tracking system (ADROIT) 482
adverse effects/reactions
definition 11–12
drug class 397
oncology 631, 632–42
rare 397
risk management strategies 397, 399–405
statistical methods 349–50
Adverse Event Reporting System (AERS) 100, 489, 561–2, 637–8
adverse events
biotherapeutics 589–97
clinical trials 216–35, 244–5, 256–61, 266, 272, 275–8
coding 223
common terminology criteria 223
data collection 218–29, 257
definitions 12–14, 423–6, 489–90
failure to recognize/communicate 218–19
laboratory data 309–33, 340
presentation of safety data 272, 275–8, 704
statistical methods 351, 352–5, 356–64
subjective symptoms 228
symptomatic/asymptomatic 223–9, 257–8
unexpected 425–6, 427, 440, 450, 464–7, 469–70, 484–5, 486, 490, 491–2, 494–500, 502, 504
unlisted 425–6
vaccines 608–10
see also serious adverse events
adverse events of special interest (AESI) 223, 277
Adverse Medicine Events Line 578
advertising 18
age effects
clinical trials 247, 254, 268–9
laboratory data 294–5, 324
pharmacological classifications 46

Edited by John Talbot and Jeffrey K. Aronson.
© 2012 John Wiley & Sons, Ltd. Published 2012 by John Wiley & Sons, Ltd.
INDEX

Agence française de sécurité sanitaire des produits de santé (AFSSAPS) 483–4
agranulocytosis 50, 241
alanine aminotransferase (ALT) 317–18, 335
albumin 320
alcohol 46, 256, 295–6
alemtuzumab 183
alkaline phosphatase (AP) 317–19
allergic reactions
clinical classifications 52–3
clinical trials 260
pharmacological classifications 48–53
pharmacovigilance 16–17
pseudoallergic reactions 52
allometry 176–8
allopurinol 54, 137
alosetron 403, 405
aluminium salts 54
aluminium-containing vaccines 65
aminoglycoside antibiotics 79
aminopterin 626
aminotransferases 317–18, 335
amiodarone 37, 45, 56, 133, 134, 191
amitriptyline 55, 81
amonafide 128
amoxicillin 52, 65
ampicillin 52
anabolic steroids 37
anaemia 328
analgesics 191
analysis without explicit criteria 84–5
anaphylactoid reactions 51, 52
anaphylaxis 16–17, 51, 606
anatomical–therapeutic–chemical (ATC) classification
547–8, 667
anecdotal reports in journals 100–1, 699–707
angelica (Angelica archangelica) 659
angiotensin converting enzyme (ACE) inhibitors 45, 46, 79–80, 93, 143, 403
animal welfare/tests 160–2, 236
Annual Safety Reports (ASR) 418, 467–8, 487
anthraquinones 659
antiangiinal drugs 191
antiarrhythmic drugs 37, 124, 189
antibiotics 191
antibodies 586, 588, 592, 594–6, 607
anticancer treatments see oncology
anticonvulsants see antiepileptic drugs
antidepressants 44, 54, 55, 124, 125
antidiabetic drugs 191
antidrug antibodies (ADA) 595–6
antiepileptic drugs 134, 191
antigen–antibody complexes 607
antihistamines 36, 79, 92
antihyperlipidaemic drugs 191
INDEX

PSURs 480
regulatory aspects 416, 449, 459–61
reporting 453–4, 459, 461, 462
risk management strategies 391–2, 399, 402
safety information 439
vaccines 603–4
benfluorex 6
benoxaprofen 4–6
benzodiazepines 45
berberine (Berberis aristata) 55
beta-asarone 659
beta-blockers 45, 79–80, 124
beta-lactam antibacterial drugs 79, 92

better regulation of medicines initiative (BROMI) 483
bevacizumab 183, 626–7
bias 98, 338–9
bilirubin 128, 130, 144, 196, 237–8, 245, 319–20, 331–2
biochemical tests 162
biological drugs 164–7, 182–6, 199–200
biotherapeutics 585–601
acute systemic inflammatory reactions 590–4
background and development 585–6
classification 587–9
delayed systemic inflammatory reactions 594
immunogenicity 585–6, 590, 595–6
localized inflammatory reactions 594–5
manufacturing methods 588–9, 596–7
monitoring for adverse events 589–97
on-target risks 590
proteins 586–7
toxicology 164–7, 182–6, 199–200
bisoprolol 80
BK2R gene 134
black cohosh (Cimicifuga racemosa) 659, 660
Black Triangle scheme 482–3, 688
Bland–Altman plots 338–9
blinding 355, 429
blood analyses see haematological testing
blood disorders 53
blood glucose 313–14
blood urea nitrogen (BUN) 309–10
blue cohosh (Caulophyllum thalictroides) 659
bone analyses 314–15, 316, 334
bone marrow 241
bone resorption and formation 316
bone-specific alkaline phosphatase 305–6
Bonferroni corrections 354
Bradford Hill guidelines 67–8
bradykinin receptors 134
bran 55
breast cancer resistance protein (BCRP) 131
breast-feeding 471
British Herbal Medicine Association (BHMA) 671
British Medical Association (BMA) 4
bromfenac 403
bupropion 5
busulfan 37
butyryl cholinesterase (BCHE) 128
C-reactive protein (CRP) 330–1, 334
C-telopeptide cross-links (CTXs) 316
caffeine–halothane test 93
calamus (Acorus calamus) 659
calcium channel blockers 36
calcium salts 54
calcium measurements 315, 340–1, 344
Canada regulations 654–5
cancer treatments see oncology
capacitabine 144
capsaicinoids 659
capsicum (Capsicum annuum) 659
carbamazepine 65, 93, 94, 137, 138–9, 142, 144, 159
carcinogenicity
herbal medicines 659, 661
toxicity 161, 166–7, 171, 179, 182, 199
cardiac electrophysiology 240
cardiac glycosides 79
see also digitalis
cardiac troponin I (Tnl) 632
cardiototoxicity 238
carvedilol 80
cascara (Rhamnus purshiana) 659
case-control studies 59, 375–9, 384, 616, 618
case-crossover method 616–17
case information 431
case report forms (CRF) 218, 220–1, 235, 253, 255, 257, 261
case reports 23, 497–8, 703–5
case-series 23
methods 379
Catapres 81
catecholamines 54
causality assessment 64–9
Bradford Hill guidelines 67–8
causality algorithms 65–7
clinical trials 233–5, 256, 266
definitive ADRs 64–5
designated medical events 65
drug-drug interactions 69
herbal medicines 668
legal aspects 534–7
oncology 629–31
pharmacovigilance 23–4
regulatory aspects 414, 428, 467
vaccines 604, 608–10, 615
celery (Apium graveolens) 659
cell-mediated reactions 51, 607
cellular adaptations 37
Center for Biological Evaluation and Research (CBER) 488
Center for Disease Control and Prevention (CDC) 141–2
Center for Drug Evaluation and Research (CDER) 488
centoxin 5
centrally authorized products 529–30
cerivastatin 6, 389
cetuximab 183
chamomile (Matricaria recutita and Chamaemelum nobile) 659
checklists 221, 227–8, 232–3, 699–707
Chelidonium majus 660–1
chemotherapy 626, 629–30
chi-squared tests 357–9
children see paediatrics
Chinese knotweed 661
Chinese medicine see traditional Chinese medicine
chloramphenicol 5, 46
chloroquine 45
chlorpromazine 191
CHM see Commission on Human Medicines
cholesterol 295, 298, 321–4
chylomicrons 322
ciclosporin 37, 45, 54, 55, 93, 131
Cimicifuga racemosa 660
CIOMS see Council for International Organizations of Medical Sciences
circadian variations 296–8
cisapride 6, 124, 133, 404
cisplatin 128
civil liability 534–7
clinical case evaluations 440
clinical classification of ADRs see DoTS classification
Clinical Experience Investigation (CEI) 502
clinical laboratory data see laboratory data
clinical practice 143–4
Clinical Study Reports (CSR) 222, 271–3
Clinical Trial Authorizations (CTA) 215, 267
clinical trials 99, 215–89
  adaptive design 241–2
  adverse drug reactions 216–18, 275–6
  adverse events 216–35, 244–5, 256–61, 266, 272, 275–8
  adverse events of special interest (AESI) 223, 277
  animal tests to humans 236
  biotherapeutics 596–7
  causality assessment 233–5, 256, 266
  checklists 221, 227–8, 232–3
  coding of adverse events 223
  common terminology criteria 223
  data collection 218–29, 235, 239, 257, 271
  databases 23
  definitions 240
  descriptive scales 229–30
  diagnoses 240
doctoration 218, 220–2, 235, 238, 253–7, 261, 267–78
dose escalation 251
drug dictionaries 550
electronic data capture 235
epidemiology 239
failure to recognize/communicate adverse events 218–20
first-in-human studies 248–51
herbal medicines 653, 656–7
instruments and methods 223–9
laboratory data 216, 222, 245–6, 258, 278, 291–2, 294, 306–8
legal aspects 539–41
oncology 633–5, 638–9
patient diary cards 225, 228–9
pharmacogenetics 140
phase I clinical trials 216, 218, 240, 242–52, 262, 292, 294, 335–6
phase II clinical trials 216, 218, 240, 252–64, 292, 335–6
phase III clinical trials 216, 218, 227, 252–64, 292, 335–6, 633–5
phase IV clinical trials 218, 227, 264–7
postmarketing drug safety 264–7
post-treatment visits 221–3, 259–60
pre-approval registration studies 252–64, 271
presentation of safety data 222, 271–80
quantification of symptoms 229–33
questionnaires 221, 225–9, 232–3, 260
regulatory aspects 418–19, 447–50, 464–6, 504
reporting systems 218–21, 227–9, 256, 261–3, 277–80
risk management strategies 238–9, 275, 391, 393–4
safety monitoring 216, 222–3, 236–8, 243–7, 252–3, 263
safety profiles 215, 262, 267–71, 281
special considerations 240–1
standard/open questions 224–5, 227–9, 280–1
statistical methods 352–6, 364–5
study populations 247–8, 254–5, 268–71, 273–4
subject safety 243–4
subjective symptoms 228, 236–7
toxicology 158, 169, 171, 200
treatment-emergent signs and symptoms 220–1, 255–6
visual analogue scales 230–1
vital signs 216, 245
withdrawals and withdrawal phenomena 221–2, 241, 258–9, 270–1, 277
Clinical Trials Directive 447–50, 464–8, 476, 481, 539
clofazimine 37
clofibrate 191
clonidine 45, 81
clozapine 54, 93, 134, 137, 404
c-o-amoxiclav 137
INDEX

co-morbidities 628–9
co-prescription 375
co-proxamol 404
co-trimoxazole 6
cocaine 55
codeine 124, 125, 144
Coding Symbols for a Thesaurus of Adverse Reaction Terms (COSTART) 553–4, 560
cognition testing 247
cohort studies 375–9, 384, 615–16, 618
collateral reactions 42–4, 94, 187
colony-stimulating factors 632
combination regimens 630, 636
comfrey (Symphytum officinale) 659
Commission on Human Medicines (CHM) 482
Commission Regulation 658/2007 456
Commissioner for the Graduated Plan 485
Committee for Medicinal Products for Human Use (CHMP)
crude mortality 254, 256, 259
legal aspects 525, 529, 530–3
oncology 637
regulatory aspects 451–2, 460–1, 477
toxicology 164
Committee on Safety of Medicines (CSM) 5, 18, 667–9, 671
Common Technical Document (CTD) 167–8, 275–7, 441–2, 446
common terminology criteria (CTC) 223, 567, 634–5
company clinical safety information (CCSI) 415–16
Company Core Data Sheet (CCDS) 433
compassionate use 471
Competent Authorities 453–4, 455–6, 459, 460–2, 477
complementary medicines 647, 652–5, 654–6, 659, 660, 661–2, 663–6
computerized provider order entry (CPOE) 88–9
conditional periods 265, 266, 267, 268–9
confidence intervals (CI) 359, 383
confounding 374–82
by indication 374
case-series methods 379
co-prescription 375
matching 378–9
regression methods 380–2
residual 375
restriction 379
stratification 379–80
study design 375–9
congenital anomalies 425
conjugation reactions 128–30
connective tissue diseases 52
consensus, assessment by 84–5
cotrol 541
Consolidated Standards of Reporting Trials (CONSORT) 99, 280, 672–3
consumer reporting 438
contact sensitization 198
containants 9, 39, 187
continuous safety monitoring 263
contractual reporting 439
contractual safeguards 520
controlled epidemiology 615–18
controlled trials 254, 280–1
convulsants 659
core risk management plans 397
Council for International Organizations of Medical Sciences (CIOMS)
benefit-risk balance 416
clinical trials 220, 233–4, 238–40, 418–19
company clinical safety information 415–16
current challenges in pharmacovigilance 416–18
definitions 567–8
development safety update reports 418–19, 442–3
drug reporting 414–15
international reporting 413–14, 415
management of safety information 418
oncology 637, 638
periodic safety update reports 415, 417–19, 432
pharmacovigilance 23, 25, 411–20
practicalities of signal detection 419–20
risk management strategies 420
site resources 690–1
website resources 690–1
working groups 412–20
Cox model 363–4
COX-2 inhibitors 389–90
cranberry products 664–5
creatinine 295, 308, 310–13
critical difference (CD) 307
CSM see Committee on Safety of Medicines cultural factors 231
cut-off points 356
cutaneous reactions 52, 197–8
cyclical regimens 630–1
cyclophosphamide 36, 37, 92, 404
cyclosporin see ciclosporin
CYP isoenzymes (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP4F2) see cytochrome P450
cystatin C 311–12, 333
cytokine 587, 592
cytokines 587, 592
CYP450 (CYP450) superfamily
clinical trials 248
drug-drug interactions 53–5
FDA approved genomic biomarkers 144
laboratory data 299
pharmacogenetics 122–7, 135, 142
toxicology 189, 198–9

INDEX

cytotoxicity
biotherapeutics 592
oncology 628, 632, 641–2
pharmacological classifications 51
toxicity 171
vaccines 607

DIA1 gene 134
dapsone 65, 134
data analysis
allometry 176–8
biological and biotechnological drugs 182–6
clinical trials 274–5, 278, 355–6
laboratory data 301–4, 339–44
NOAEL with conventional dosimetry 178–9
NOAEL and relative systemic exposure 179–80
observational studies 373–84
pre-authorization risk assessment 181
predictive ability of non-clinical studies 181–6
small-molecule drugs 181–2
systematic reviews 98
toxiology 174–86
variation and quality control 301–4
see also statistical methods
data collection
CIOMS working groups 412–20
clinical trials 218–29, 235, 239, 257, 271
ICH guidelines 418, 420–46
regulatory aspects 412–47
standardization and harmonization 412–47
systematic reviews 98
data mining 25, 99, 239, 351, 365
data monitoring committees (DMC) 261–2
data privacy legislation 462, 537–8
databases 23, 99, 395, 637–8, 672, 695
deaths see fatalities
definitions, types of 7
descriptive 7
extensional 7
intensional 7
operational 7
ostensive 7
stipulative 7
definitive ADRs 64–5
degradation products 39
delayed reactions
biotherapeutics 594
clinical trials 222
pharmacological classifications 45, 48, 94
toxiology 199
see also cell-mediated reactions
deoxyxypyrindoline (DPD) 314, 316
dependence phenomena 270–1
derivatives 39
descriptive scales 229–30
designated medical events 25, 65
detailed Description of the Pharmacovigilance System (DDPS) 454–5, 521
Development Core Safety Information (DCSI) 419, 638
development risk management plan (DRMP) 271
development safety update reports (DSUR) 418–19, 442–3
developmental tests 163
dexfenfluramine 6
dextrose 36
diabetes 619
diagnostic pathology 306–7
3,4-diaminopyridine 81
diary cards 225, 228–9
diazepam 124, 189
diclofenac 131, 159, 191
dictionaries 545–72
adverse drug reaction dictionaries 551–4
Anatomical–Therapeutic–Chemical classification 547–8
characteristics and types 545–7
common terminology criteria for adverse events 567
definitions of ADR terms 567–8
disease classifications 554–7, 560
drug dictionaries 446, 547–54
electronic health records 568–70
EudraVigilance medicinal product dictionary 551
MedDRA 554, 557–67
regulatory aspects 561–2
SNOMED 568–70
standard product information 570–1
translations 563
WHO drug dictionaries 547–50
WHO-ART 551–3, 568
dietary factors 298
dietary supplements 653–4
diethylene glycol 4, 5
diethylstilbestrol 37, 45
digoxin 44, 45, 79
digoxin 36, 54, 131
dihydropyrimidine dehydrogenase (DPD) 128
deficiency 142, 144
dimesulide 191
diododiethyl tin 5
diphtheria–tetanus–pertussis/Haemophilus influenzae type b (DTP/Hib) vaccine 606, 612, 616–17
dipyrone 137
direct evidence 67–8
direct pharmacodynamic interactions 58
direct-to-consumer advertising 18
directed acrylic graphs (DAG) 377–8, 382–3
discovery see drug discovery
discussion sections 705
disease classifications 554–7, 560
disease management programmes 23
disease-related susceptibility 46
INDEX

<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>715</td>
<td>disembedding mechanisms 573–4</td>
</tr>
<tr>
<td></td>
<td>disopyramide 133, 134</td>
</tr>
<tr>
<td></td>
<td>disproportionality 25</td>
</tr>
<tr>
<td></td>
<td>distribution 35–6, 41–2, 56–7, 91–2</td>
</tr>
<tr>
<td></td>
<td>diterpenes 659</td>
</tr>
<tr>
<td></td>
<td>diuretics 54, 403</td>
</tr>
<tr>
<td></td>
<td>see also loop diuretics, spironolactone, thiazide</td>
</tr>
<tr>
<td></td>
<td>diuretics, triamterene</td>
</tr>
<tr>
<td></td>
<td>Dixarit 81</td>
</tr>
<tr>
<td></td>
<td>documentation</td>
</tr>
<tr>
<td></td>
<td>clinical trials 218, 220–2, 235, 238, 253–7, 261, 267–78</td>
</tr>
<tr>
<td></td>
<td>electronic data capture 235</td>
</tr>
<tr>
<td></td>
<td>laboratory data 294</td>
</tr>
<tr>
<td></td>
<td>oncology 641</td>
</tr>
<tr>
<td></td>
<td>risk management strategies 395</td>
</tr>
<tr>
<td></td>
<td>see also medical records; prescriptions; reporting systems</td>
</tr>
<tr>
<td></td>
<td>dofetilide 134</td>
</tr>
<tr>
<td></td>
<td>dopa decarboxylase inhibitors 92</td>
</tr>
<tr>
<td></td>
<td>dopamine receptor agonists 49</td>
</tr>
<tr>
<td></td>
<td>dopamine receptor antagonists 45, 92</td>
</tr>
<tr>
<td></td>
<td>see also antipsychotic drugs</td>
</tr>
<tr>
<td></td>
<td>dopamine receptors 134</td>
</tr>
<tr>
<td></td>
<td>dosage regimens 15</td>
</tr>
<tr>
<td></td>
<td>dose escalation 251</td>
</tr>
<tr>
<td></td>
<td>dose-response relationships 33, 34–5</td>
</tr>
<tr>
<td></td>
<td>clinical trials 216, 243, 251, 253, 264–5</td>
</tr>
<tr>
<td></td>
<td>DoTS classification 42–4, 94</td>
</tr>
<tr>
<td></td>
<td>preventability 94</td>
</tr>
<tr>
<td></td>
<td>toxicology 164, 175, 178–9, 187–99</td>
</tr>
<tr>
<td></td>
<td>dossier compilation 167–8</td>
</tr>
<tr>
<td></td>
<td>DoTS classification 35, 38, 42–50</td>
</tr>
<tr>
<td></td>
<td>applications 48–50</td>
</tr>
<tr>
<td></td>
<td>dose-relatedness of ADRs 42–4, 94</td>
</tr>
<tr>
<td></td>
<td>preventability 91–7</td>
</tr>
<tr>
<td></td>
<td>risk management strategies 399–400</td>
</tr>
<tr>
<td></td>
<td>susceptibility 42–4, 46, 48, 93–5</td>
</tr>
<tr>
<td></td>
<td>time-relatedness of ADRs 43–5, 47–8, 91, 93</td>
</tr>
<tr>
<td></td>
<td>double blinding 251</td>
</tr>
<tr>
<td></td>
<td>doxorubicin 131, 632</td>
</tr>
<tr>
<td></td>
<td>DPD see dihydropyrimidine dehydrogenase</td>
</tr>
<tr>
<td></td>
<td>drug class 70–1, 78–80, 191, 368, 397</td>
</tr>
<tr>
<td></td>
<td>drug development</td>
</tr>
<tr>
<td></td>
<td>drug safety during 141</td>
</tr>
<tr>
<td></td>
<td>non-standard non-clinical tests 173–4</td>
</tr>
<tr>
<td></td>
<td>species selection 172, 175</td>
</tr>
<tr>
<td></td>
<td>standard non-clinical tests 172–3</td>
</tr>
<tr>
<td></td>
<td>statistical methods 172, 350</td>
</tr>
<tr>
<td></td>
<td>strategic considerations 171</td>
</tr>
<tr>
<td></td>
<td>toxicity 171–4</td>
</tr>
<tr>
<td></td>
<td>validity and relevance 174–5</td>
</tr>
<tr>
<td></td>
<td>drug–device interactions 3, 15, 53</td>
</tr>
</tbody>
</table>
INDEX

716

EIDOS classification (Continued)

risk management strategies 400

sequelae (adverse reactions) 35–6, 42

elderly patients see geriatrics
electrocardiography (ECG, EKG) 240, 245
electroencephalography (EEG) 243
electrolyte/fluid balance 246, 313
electronic data capture (EDC) 235
electronic data reporting 414–15, 463–4
electronic health/medical records 88–9, 568–70

electronic standards for the transfer of regulatory information (ESTRI) 446

Eleutherococcus ginseng 648
EMBASE database 99
Empirical Bayes Geometric Mean (EBGM) 370–1

Enbrel 189
ENCePP see European Network of Centres for Pharmacoepidemiology and Pharmacovigilance

end-points of clinical efficacy 256, 265–6
endotoxins 605
enzymes 40, 588
eosinophilia myalgia syndrome 5, 187
eosinophils 329

epidemiology
clinical trials 239
herbal medicines 672–3
oncology 625–6, 635–6, 638
societal factors 574–5
vaccines 610–11, 615–18
epigenetic variations 122
epinephrine see adrenaline
epoetin alfa 189
Eprex 189
Erbitux 183
Erypo 189

errors 26
see also medication errors
erythrocytes 317–19, 327, 330–1, 334
erythromycin 134
estimated glomerular filtration rate (eGFR) 310–11
estrogens 134
etanercept 183
ethambutol 49
ethnicity 298–9
ethyl methanesulphonate 187
1,1-ethylidenebis[L-tryptophan] 36
etomidate 5, 404
EudraVigilance 463–5, 551, 690
European Centre for Disease Control (ECDC) 620
European Medicines Agency (EMA) 80
clinical trials 238, 265, 270
herbal medicines 650–1
legal aspects 512–13, 524–5, 527–9, 532
pharmacogenetics 141–2

regulatory aspects 445, 450–2, 469, 480–1
risk management strategies 406
website resources 689, 697
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) 695–6
European Public Health Alliance (EPHA) 690
European Risk Management Strategy (ERMS) 695
European Scientific Co-operative on Phytotherapy (ESCAP) 646
European Union (EU) directives
anticipated changes to regulations 478–81
centrally authorized products 529–30
civil liability 534–7
clinical trials 215
Clinical Trials Directive 447–50, 464–8, 476, 481, 539
Competent Authorities 453–4, 455–6, 459, 460–2, 477
consent and risk 541
Council directive 95/46/EC 462
Council directive 2001/20/EC 447–50, 538–40
Council directive 2001/83/EC 448–9, 452–62, 466, 468–9, 472, 476–9, 512, 514–18, 522, 524–33, 540, 649, 651
Council directive 2004/24/EC 650
Council directive 2004/27/EC 448–9, 452–62
Council directive 2005/28/EC 538–40
Council directive 2010/84/EU 511–15, 517–18, 521–2, 528–34, 538, 540
Council regulation (EC) 658/2007 526–7
Council regulation (EC) 726/2004 447–9, 452–62
data privacy legislation 462, 537–8
definitions 2, 517–18
electronic data reporting 463–4
electronic standards for the transfer of regulatory information 689
enforcement and sanctions 524–8
failures to meet pharmacovigilance requirements 522–4
herbal medicines 646, 649–50
investigational medicinal products 464–8
legal aspects 511–43
legal basis and regulatory framework 447–8
marketed products 466–76, 530–3, 540–1
Marketing Authorization Holders 448–9, 453–60, 465–81, 513–41
nationa
periodic safety update reports (PSURs) 449, 455, 459–61, 468, 472–6, 480
pharmacovigilance 447–81
specific guidelines 452–62
post-authorization safety studies 457–8, 459, 476–80
powers and procedures 528–34
purposive interpretation 514–15
relationship between law and guidelines 515–17
INDEX

reporting systems 447–8, 460–81
research product safety 538–41
responsibilities and obligations 519–22, 538–9
risk management strategies 390, 406, 456–60, 474, 480
toxicology 158–9, 165–6, 168–70
uncertainties 515
Volume 9A rules on medicinal products 452–62, 469–70, 474–8, 514, 516–18, 520

see also Committee for Medicinal Products for Human Use; European Medicines Agency
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) 142

excipients 10, 39
exclusion criteria 335–6
excretion interactions 57
exercise 299
exogenous factors 46
exotoxins 605
expedited reporting
clinical trials 263
European Union directives 463–72, 477
France regulations 484
Germany regulations 486
ICH guidelines 426–9, 438–41, 464–5, 468–9
Japan regulations 504–5
USA regulations 491, 494, 502
explicit lists of harmful treatments 84–5, 89
exposure multiples 179
extensive metabolizers 124
external quality control 303–4
exercise 299
extracellular alterations 40, 41
extracellular deposition 65
extrinsic species in adverse drug reactions 35–6, 37–41, 91–2
false negatives/positives 306, 350, 353
fatalities
clinical trials 261, 277
definitions 424
frequencies of ADRs 73, 74
regulatory aspects 490, 491, 492, 502, 504
FCγRIIa gene 134
felbamate 197
fenofibrates 65
feverfew (Tanacetum parthenium) 659
fevers 52
fexofenadine 92
first-dose effects 15, 45, 47, 92, 400
first-in-human (FIH) studies 170, 248–51
Fisher’s exact test 359
fixed-interval scales 229–30
flecainide 5
flosequinan 5
flucloraclitil 137
fluorouracil 37, 128, 142, 144
fluoxetine 191
flutamide 65
follicle-stimulating hormone (FSH) 299–300, 587, 588
Food and Drug Administration (FDA) 4
clinical trials 238, 241, 249–50, 264–6, 268
dictionaries 553–4, 561–2, 570–1
FDA Amendments Act 2007 499–500
frequencies of ADRs 69–70
herbal medicines 654
oncology 637
pharmacogenetics 127, 141–4
pharmacovigilance 18
regulatory aspects 445, 487–8, 494–500
reporting systems 100
risk management strategies 389, 398–9
societal factors 575, 578
statistical methods 351, 367, 371
toxicology 164–5, 168–70, 179–80
unlicensed indications and off-label uses 80
vaccines 611–12
foodstuffs 3, 53, 56
France regulations 483–4
frangula (Frangula alnus) 659
frequencies of ADRs 69–77
benefit-to-harm balance 73–7
clinical trials 216, 230
definition and classification 20–1
drug class 70–1
fatalities 73, 74
general practice 72
herbal medicines 657–8
hospitalization 73
in-patients 73
medication errors 29
physiological systems 70–1
reporting systems and surveys 69–72
frequentist disproportionality methods 365–9, 385
functional tests 162
fundoscopy 247
gastrintestinal effects 659
G6PD see glucose-6-phosphate dehydrogenase
gamma glutamyltranspeptidase (GGT) 317–18, 335
gamma Poisson shrinkers 370–1
gefitinib 131

gender effects
clinical trials 247
hypersusceptibility 198
laboratory data 294–5, 321, 324
pharmacological classifications 46
general practice 59–60, 72
General Practice Research Database (GPRD) 23, 637–8, 672
website resources 694–5
INDEX

- general sales list (GSL) medicines 649
- genetic factors 46, 122–3, 248
  
  see also pharmacogenetics
- genetic screening 137
- genomic biomarkers 144
- genotoxicity testing 161, 170, 175, 182
- genotype testing 129
- gentamicin 94
- geriatrics 254, 268
- Germany regulations 485–7
- Gingko biloba 55, 663–4
- ginseng (Panax ginseng) 55
- glibenclamide 55
- glipizide 189
- Global Advisory Committee on Vaccine Safety (GACVS) 620
- glomerular filtration rate (GFR) 310–12
- glucocorticoids 37, 45, 50, 55, 93, 404, 632, 641
- glucose 313–14, 332, 334
- glucose-6-phosphate dehydrogenase (G6PD) 63, 122, 134, 144
- glucuronidation 198
- glycosylation patterns 185
- gold salts 137
- good case management practices 440–1
- good clinical practice (GCP) 267, 444–5
- good laboratory practice (GLP) 158–62, 293
- good manufacturing practice (GMP) 650, 652
- GPRD see General Practice Research Database
- Granada schema 90
- granulocyte colony-stimulating factor (G-CSF) 588
- granulocytes 329
- grapefruit juice 6, 46, 54, 56
- greater celandine 660–1
- groups of companies 521, 524
- growth hormone releasing hormone (GHRH) 587
- GSTM1 glutathione S-transferase 128
- guar gum (Cyanopsis tetragonolobus) 55
- Guillain–Barré syndrome (GBS) 607, 609, 619
- H1N1 influenza virus 397
- haemolytic anaemia 328
- haemolytic hyperbilirubinaemia 320
- Hallas’ avoidability criteria 86
- haloperidol 134
- halothane 134
- Han Chinese 137
- harmonization of laboratory data 337–9
- harm assessment 75
- hazard ratios (HR) 361, 363
- He Shou Wu 661
- health insurance programmes 23
- healthy volunteers 294
- heparin 134
- hepatic hyperbilirubinaemia 320
- hepatitis 197, 246–7, 616–17, 661
- hepatotoxicity
  
  clinical trials 238, 240–1, 245
  
  herbal medicines 658–61
  
  hypersusceptibility 195–7
  
  see also liver
- Hepler–Strand criteria 90
- herbal dictionaries 550
- Herbal Medicinal Products Committee (HMPC) 650–1
- herbal medicines 645–83
  
  access to and usage 655–6
  
  adverse drug reactions 652, 655, 656–67, 670–1
  
  clinical trials 256
  
  communication/disclosure of use 656, 673
  
  composition and constituents 647–8, 663, 665–6
  
  definitions and descriptions 9, 646–7
  
  drug–drug interactions 3, 53, 55, 663–5
  
  future prospects 674–5
  
  hepatotoxicity 658–61
  
  international monitoring 667
  
  nephrotoxicity 659, 661–2
  
  pharmacoepidemiology 672–3
  
  pharmacovigilance 3, 9, 645, 651–2, 666–75
  
  phototoxicity 659, 662
- prescription event monitoring (PEM) 671–2, 675
- public perceptions and responses 673
- quality control 665–6
- regulatory aspects 648–55
- reporting systems 655, 656, 666–73
- responding to safety concerns 673
- signal detection and assessment 668–9
- specific patient groups 662–3
- types and characteristics 647–8
- Herceptin 183
- herd immunity 603, 604
- HERG (KCNH2) gene 134
- HERG potassium channels 133
- hierarchies of evidence 351
INDEX

719

high-density lipoprotein (HDL) 322–4

high-level terms (HLT) 552–3, 559–60, 564–7, 570

HIV protease inhibitors 55

HIV-1 reverse transcriptase inhibitors 137

HIV/AIDS

clinical trials 246–7

herbal medicines 657

toxicology 171, 196, 199

vaccines 612

HLA genes 93, 136–7, 138, 141–5

HLA-B*1504 genotype 144

HLA B*5701 genotype 137, 142, 144, 403

HMG CoA reductase inhibitors 79

see also statins

Hong Kong Chinese 137

hormone replacement therapy (HRT) 358–63

hormones 587–8

horse-chestnut \( (Aesculus hippocastanum) \) 659

hospital reporting systems 60

hospitalization 17–18, 73, 424–5

HTR2A gene 134

HTR2C gene 134

human epidermal growth factor receptor 2 (HER-2) 181

human ether-a-go-go (HERG) potassium channels 133

human immunodeficiency virus see HIV

human papillomavirus (HPV) 613, 627

Humira 184

hydralazine 128, 137, 189

5-hydroxytryptamine (serotonin) receptors 134

hyperbilirubinaemia 128, 130, 144, 196, 320

Hypericum perforatum 55, 648, 651, 657, 662–4

hypersensitivity

biotherapeutics 591, 593, 597

classical trials 260

herbal medicines 659

oncology 631

pharmacogenetics 136–8, 142

pharmacological classifications 16–17

toxicology 188, 195, 198

vaccines 606, 607

hypersusceptibility reactions 15, 17, 33, 42–4, 45, 47, 48, 94, 95, 96 see also susceptibility

hypnotics 46

hypothyroidism 324

ibuprofen 83, 191

ICH see International Committee on Harmonization

identification information 431

idiosyncrasy 16

if functions 341–3

ifosfamide 92

Illicium species 665

immediate hypersensitivity see anaphylaxis

immediate reactions 45, 47, 91

immortal time bias 376

immune-complex reactions 51, 607

immune-mediated effects 194–5, 201, 606–7

Immunization Monitoring Programme Active (IMPACT) system 614

immunization programmes see vaccines

immunogenicity

biotherapeutics 585–6, 590, 595–6

clinical trials 241

hypersensitivity 136–7

toxicology 185

immunoglobulin G gene 134

immunoglobulins (Ig) 185, 591–2, 596, 607

immunological proteins 41

immunosuppression 186

imputability assessments 484

in silico predictions 199

incidence rates 278, 360, 364

see also frequencies of ADRs

incidence risk ratio 357

included names/terms 552–3

ineterminate signals 23–4

indinavir 55, 65, 131, 159, 196

indirect pharmacodynamic interactions 58

individual case histories 435–6

individual case safety reports (ICSR)

dictionaries 551–2

regulatory aspects 429–32, 438–9, 454–5, 459, 463, 470

website resources 693

indoprofen 5

induction of drug metabolism 57

infections 64–5, 471–2, 505

infliximab 184

influenza vaccines 617–18

information bias 374, 385

information technology 84–5, 88–9

inhibition of drug metabolism 57

injection site reactions 594–5

Inman’s seven deadly sins 60–1, 219

inorganic phosphate 315–16

in-patient frequencies of ADRs 73

inspections 525–6

insulin 36, 37, 94

insulin-dependent diabetes (IDDM) 619

intensity of ADRs 18–20, 229–31

interactions see drug-device interactions, drug-drug interactions, drug-food-interactions, drug-herb/herbal medicine interactions

interim analyses 260, 263

intermediate-density lipoprotein (IDL) 322–4

intermediate metabolizers (IM) 124

intermediate reactions 45, 47–8, 92

internal quality control (IQC) 302–3

International Birth Date (IBD) 433, 473–4, 505

International Classification of Diseases (ICD) 554–7, 560

Inorganic phosphate 315–16
International Conference on Harmonization (ICH)
anticipated changes to regulations 478
clinical trials 263, 266–7, 269, 271–3
definitions 423–6
development safety update reports 442–3
dictionaries 446, 561–2, 565
electronic standards for the transfer of regulatory information 446
expedited reporting 426–9, 438–41, 464–5, 468–9
expert working groups 421–2
good clinical practice 444–5
individual case safety reports 429–32, 438–9
long-term treatment of non-life-threatening conditions 443
medical terminology 445–6
oncology 638
origins and objectives 420–1
periodic safety update reports 432–8, 442, 474–5, 498–9
pharmacovigilance 411–12, 418, 420–46
pharmacovigilance plans 441–2, 458
post-approval drug safety 438–41
risk management strategies 389
standardization and harmonization 443
website resources 691–2
International Federation of Clinical Chemistry (IFCC)
304–6
International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) 413–14, 420, 562
International Normalized Ratio (INR) 321, 664–5
International reporting 413–14, 415
International Sensitivity Index (ISI) 321
International Society of Epidemiology (ISPE) guidelines 700
International Society of Pharmacovigilance (ISoP) 696 guidelines 700
Internet reporting 439
interventional clinical trials see clinical trials
intracelluar drug deposition 65
intra-individual biological variations 307–8
intrinsic species 35–6, 40–1, 91–2
investigational medicinal products (IMP) 464–8
Investigational New Drugs (IND) 215, 242, 267, 418, 487, 491–4
investigational products 502
Investigator Brochure (IB) 267, 419, 444–5, 641
investigator obligations 444, 538–9
investigator-sponsored studies (ISS) 267
iodipamide 45
ion channels/transporters 41
irinotecan 55, 128, 130, 131, 142, 144
ischaemic heart disease 49
isoniazid 128, 144, 189
isotretinoin 93, 403
ispaghula husk (Plantago ovale) 55
Japan regulations 500–505
investigational products 502
legal basis and regulatory framework 500–2
marketed products 502–5
reporting systems 501–2, 504–5
Japanese Maintenance Organization (JMO) 562–3
Joint Expert Committee on Food Additives (JECFA) 179
journals 100–1, 279–80, 699–707
Kaplan–Meier estimates 361–4
kava kava (Piper methysticum) 6, 651, 659, 663, 665
ketonuria 332
kidneys see renal function tests
knowledge-based errors 30–1
KvLQT1 (KCNQ1) gene 134
labelling
frequencies of ADRs 70, 72
herbal medicines 654, 656, 663, 665
oncology 640–1
pharmacogenetics 142–3
rules 570–1
unlicensed indications and off-label uses 80–2
labetalol 80
laboratory data 291–348
adverse events 309–33, 340
age, effects of 294–5, 324
alcohol intake, effects of 295–6
analytical variation and quality control 301–4
bone analyses 314–15, 316, 334
circadian and seasonal variations 296–8
clinical trials 216, 222, 245–6, 258, 278, 291–2, 294, 306–8
data analysis and presentation 339–44
dietary factors, effects of 298
efficacy testing 293
ethnicity, effects of 298–9
exclusion criteria and panic levels 335–6
exercise, effects of 299
gender, effects of 294–5, 321, 324
haematology 325–31, 333–5, 345
harmonization of data 337–9
healthy volunteers 294
intra-individual biological variations 307–8
kidney function, effects of 309–14, 333–5
lipids and lipoproteins 321–4, 334
liver function, effects of 294–5, 316–21, 334–5
menstruation, effects of 299–300
posture of patient/subject 296
pre-analytical factors 294–300
purposes of laboratory tests 292–4
reference ranges 304–7, 335–6, 345–6, 356
safety monitoring 292–3
safety profiles 334
INDEX

sampling strategies 300–1
smoking, effects of 300
stability 301
statistical methods 338–44, 356
stress, effects of 300
substance abuse, effects of 298
test selection 333–5
thyroid function, effects of 324–5, 334
urinalysis 331–3, 334
lamotrigine 137
late reactions 45, 48, 92
latent factors 31
legal aspects
application in EU member states 511–14
centrally authorized products 529–30
civil liability 534–7
consent and risk 541
definitions 517–18
enforcement and sanctions 524–8
European Union directives 511–43
failures to meet pharmacovigilance requirements 522–4
groups of companies 521, 524
inspections 525–6
interpretation of EU law 514–15, 517–18
marketed products 530–3, 540–1
marketing authorization holders 513–41
nationally authorized products 530
pharmacovigilance 511–43
powers and procedures 528–34
qualified person responsible for pharmacovigilance (QPPV) 522
relationship between law and guidelines 515–17
research product safety 538–41
responsibilities and obligations 519–22, 538–9
lefunomide 124
lenaldomide 627
leukocytes 328–30, 333
levamisole 137
levodopa 92
licensed herbal medicines 649–52
licensing 70, 72, 80–2, 488
licorice see liquorice
liferoot (Senecio aureus, S. scandens) 659
life-threatening events 17–19, 25, 262, 424
Likert scales 229–30
line listings 435
lipids 321–4, 334
lipoproteins 321–4
liquorice (Glycyrrhiza glabra) 55
literature reports 438, 495
literature reviews 470
lithium 46, 54, 55, 303
live vaccines 605
liver
anatomical detail 316–17
bilirubin 237–8, 319–20
clinical trials 237–8, 245
function tests 294–5
laboratory data 309–14, 316–21, 333–5
liver enzymes 317–19
prothrombin time 321
total protein and albumin 320
local tolerance testing 162
localized inflammatory reactions 594–5
log-likelihood ratio (LLR) 372–3
log-rank tests 362–4
long-term follow-up 221–3, 259–60, 352
long-term safety studies 253, 266
long-term treatment of non-life-threatening conditions 443
loop diuretics 79
losartan 189
lovastatin, 55
low-density lipoprotein (LDL) 322–4
lowest level terms (LLT) 557–60, 563–7, 570
lung disease 50
lupus erythematosus-like syndrome 128, 137
Lyell’s syndrome 5
lymphocytes 329
MabCampath 183
MabThera 183
macrocytic anaemia 328
macrophagic myofasciitis (MMF) 609
magnesium salts 54
maintenance and support services organization (MSSO) 562–3
major histocompatibility complex (MHC) 195, 197
malathion 36
malignant hyperpyrexia/hyperthermia 93, 134
MAO see monoamine oxidase
marketed products
legal aspects 530–3, 540–1
marketing across multiple states 530–3
regulatory aspects 468–76, 494–9, 502–5
Marketing Authorization Applications (MAA) 168, 270, 448
Marketing Authorization Holders (MAH)
dictionaries 551
legal aspects 513–41
regulatory aspects 433–4, 448–9, 453–60, 465–81
mass-balance studies 244
matching 378–9
maximum human dose (MHD) 178–80
maximum tolerated dose 167
mean cell haemoglobin (MCH) 294, 327, 334
mean cell volume (MCV) 327
measles–mumps–rubella (MMR) vaccine 398, 606–7, 610–11, 613, 617, 619
measures taken abroad 50
mechanistic classification of ADRs see EIDOS classification
mechanistic evidence 68
mechanistic studies 175, 181
MedDRA 554, 557–67
  background and development 557
  data entry/retrieval 563–5
  maintenance and support services organization 562–3
  oncology 634–5
  periodic safety update reports 566–7
  regulatory aspects 445–6, 459, 463, 474, 561–2
  scope 557
  standard product information 570
  structure 557–61
  translations 563
media publicity 63–4, 604
medical records 88–9, 91, 93, 246–7, 254
Medical Research Council (MRC) 4
medical terminology EWG 445–6
medically important adverse events 425
medication errors 25–32
  classification 29–31
  detecting and reporting 31–2
  frequencies and outcomes 29
  latent factors 31
  pharmacovigilance 13–14
  prescribing faults 26–9, 137
  prescription errors 26–9
  prevention 29–31, 84–6
  regulatory aspects 473
  terminology and definitions 26–9
medication-related factors 87–8
medicinal products 8–9, 15, 26
Medicines Act (New Zealand) 653
Medicines Act (UK) 649, 651
Medicines and Healthcare products Regulatory Agency (MHRA) 80, 100
  herbal medicines 649–52, 660, 662, 667–71
  laboratory data 292
  legal aspects 523
  oncology 637
  regulatory aspects 482
  societal factors 578
  toxicology 158
  vaccines 612–13
  website resources 695
Medicines Monitoring Unit (MEMO) database 23, 672
MEDLINE database 99
Medsafe 653
MedWatch 23, 489, 578
mefloquine 46
melphalan 36
memory-based errors 30–1
menstruation 299–300
mental health 256
mercaptopurine 93, 128, 142, 403
mesna 81, 92, 404
meta-analyses 364–5, 383–4
metabolism interactions 57
metabolism studies 175
metabolites 192–4, 197, 200–1
metamfetamine 55
metformin 55, 191
methaemoglobin reductase 134
methotrexate, 65, 131, 134
N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 187
methyldopa 45, 403
methylenedioxymetamfetamine 37
methylsergide 37
metipranolol 5
metoprolol 80
mibefradil 6
microalbumin 312–13
microcytic anaemia 328
microdosing studies 242
microRNA profiles 122
Minimal Anticipated Biological Effect Level (MABEL) 167, 175
Ministry of Health, Labour and Welfare (MHLW) 421, 500–505
MinK (KCNE1) gene 134
MIRPI1 (KCNE2) gene 134
mistletoe (Viscum album) 659
misuse of medicinal products 472, 518
mitochondrial toxicity 190–2
mitogenicity 659
mitoxantrone 36
MMR vaccine 608
molecular interactions 40–1
monitoring
  biotherapeutics 589–97
  clinical trials 216, 222–3, 236–8, 243–7, 252–3, 263
  definitions 21–2
  regulatory aspects 454, 455–6, 479
  risk management strategies 400–2
  monoamine oxidase (MAO) inhibitors 37, 54
  monoclonal antibodies 79
  monocytes 330
  morphine 46, 125
MPTP 191
MTHFR gene 134
multi-item gamma Poisson shrinkers (MPGS) 371
multidisciplinary testing 165
multidrug resistance associated protein 1 (MRP1) 131
multidrug resistance associated protein 2 (MRP2) 131
multidrug resistance (MDR) 131, 132
multiple ascending dose (MAD) 243
multiple determinant hypothesis 192–3
INDEX

723

multiple statistical tests 354–5
mumps vaccine 65
myelin basic protein (MBP) 607
myelosuppression 128–9
myoglobulinuria 331
myopathies 131–2
N-acetyl-β-D-glucosaminidase (NAG) 312
N-acetyl-p-benzoquinoneimine 36
N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 187
N-telopeptide cross-links (NTx) 316
nabumetone 191
nafidrofuryl 6
naloxone 54
named-patient use 23, 264, 471
Naranjo’s causality algorithm 66
narratives 440, 496–8
NAT variants 144
NAT2 N-acetyl transferase 128
natalizumab 184
National Cancer Institute (NCI) toxicity criteria 19, 635
National Competent Authorities (NCA) 460–1, 465–6, 470
National Health Service (NHS) 580–1
National Institute of Medical Herbalists (NIMH) 671
nationally authorized products 530
natural health products (NHP) 654–5
nelfazodone 191
negligence 534–6
nelfinavir mesylate 187
nomifensine 5
non-clinical tests 161–3
data interpretation 174–6
drug development 172–4
guidelines 165
non-standard 173–4
predictive ability 181–2
small-molecule drugs 181–2
validity and relevance 174–5
non-esterified fatty acids (NEFA) 322
non-human sequences 185
non-IgE-mediated anaphylaxis 51, 52
non-medical case reports 439
non-small-cell lung cancers 629
non-specific monitoring 236–7, 252
non-steroidal anti-inflammatory drugs (NSAIDs) 65, 78, 79, 126, 191
nortriptyline 131
notifedipine 45
nucleic acids 40
nucleoside reverse transcriptase inhibitors (NRTIs) 171, 191
number needed to treat (NNT) 73–7, 358–9
objective findings 237
observational studies 99
confounding 374–82
information bias 374, 385
meta-analyses 383–4
other forms of bias 382–3
regulatory aspects 500
societal factors 576
statistical methods 351, 373–84, 385
obstetrics
clinical trials 269–70
herbal medicines 655, 662–3
regulatory aspects 441, 471
risk management strategies 396–7, 402, 405
odds ratios (OR) 75–6, 357–9, 364
off-label usage 80–2, 398, 631
off-target risks 590
omeprazole 189
oncology 625–44
adverse effects 631, 632–42
assessment of adverse effects data 635–41
benefit-to-harm balance 640
chemotherapy 626, 629–30
combination regimens 630
co-morbidities 628–9
data sources and types 632–5
nitrogen mustards 626
NNT, NNT\textsubscript{B}, NNT\textsubscript{H} see number needed to treat
No Observed Adverse Effect Level (NOAEL) 167, 171, 175, 178–80, 250–1
No Observed Effect Level (NOEL) 167
nomifensine 5
off-label usage 80–2, 398, 631
off-target effects 590
oncology (Continued)
detection and verification of signals of harm 639–40
drug tolerance and resistance 631
epidemiology 625–6, 635–6, 638
extravasation reactions 65
management of adverse effects 632
mitochondrial toxicity 191
novel modes of action 631–2
off-label and unlicensed uses 631
patient considerations 627–8
pharmacovigilance 636–8
placebo-controlled trials 639
pretreatments 628–9
prevention of adverse effects 632
previous interventions 628
recent advances 626–7
remedial actions and communication 640–1
risk management strategies 638, 641
systematic reviews 639
TNM classification 629–30
treatment regimens 629–31, 636
on-line safety monitoring 263
on-target risks 589–90, 592
open questions 224–5, 227–9, 280–1
opiates 45
opioid receptors 134
opioids 55, 125, 189
OPRM1 gene 134
optic neuropathy 49
oral contraceptives 54, 55, 74–5, 398
oral polio vaccine (OPV) 608, 609–11
organic anion transporter polypeptide 1B1 (OATP1B1) 131
Organisation for Economic Cooperation and Development (OECD) 158
organized reporting 23
orphan diseases/drugs 82–4, 394
Osmosin 5
osteocalcin 314–16
osteoporosis 50, 316
outcomes 35–6, 42
outliers 341
over-the-counter (OTC) products 256
overdoses 473, 495
overmatching 379
oversulphated chondroitin sulphate (OSCS) 187, 398
oxicams 137
oxidation reactions 123–7, 191–2
oxprenolol 80
P-glycoprotein 131, 132
paediatrics 254, 268, 471
pain 231, 248
Panax ginseng 55
pandemics 397
panic levels 335–6
panitumumab 183
paracetamol 36, 37, 59, 191
parallel evidence 68
parathormone (PTH) 315
parent–child reports 431
parenteral administration 594–5
paroxetine 54
Passiflora incarnata 663
passive surveillance systems 612–13
pathological effects 37, 49
parent diary cards 225, 228–9
patient exposure information 434–5
patient identifiability 440
Patient Information Leaflets (PIL) 395–6, 582, 641
patient selection 254–5
patient subgroups 254, 268–70, 273–4
patient trust 579–81
PBGD gene 134
pegfilgrastim 184
pemylation 185
penicillamine 137
penicillins 44, 55, 79, 93, 94
perception of risk 77–8
perhexiline 124, 125
periodic safety update reports (PSURs)
CIOMS working groups 415, 417–19
dictionaries 566–7
European Union directives 449, 455, 459–61, 468, 472–6, 480
France regulations 484–5
Germany regulations 487
herbal medicines 651
ICH guidelines 432–8, 442, 474–5, 498–9
Japan regulations 505
oncology 637
USA regulations 498–9
persistent adverse events 221–3
personal data privacy 537–8
P-glycoprotein (P-gp) 131
pH measurements 331
PHARMA checklist 700–2
pharmaceutical companies
investigator-sponsored studies 267
laboratory data 291, 306–7
legal aspects 521, 524
pharmacogenetics 139–41
regulatory aspects 411, 484
risk management strategies 391
societal factors 578, 582–3
Pharmaceutical Information and Pharmacovigilance Association (PIPA) 696–7
pharmaceutical interactions 54, 56
Pharmaceuticals and Medical Devices Agency (PMDA) 500
pharmacodynamics 54, 58, 122–3, 133–8, 158
INDEX 725

Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT) 23

pharmacoepidemiology 635–6, 638, 672–3, 695–6
pharmacogenetics 121–56
antidepressants and opioids 125
antipsychotic drugs 135
clinical practice 143–4
clinical trials 140
cytochrome P450 superfamily 122, 123–7, 135, 142
drug discovery 139–40
drug metabolizing enzymes 123–30
drug safety profiles 140–1
drug transporters 130–2
efavirenz-related toxicity 127
historical review 121–2
hypersensitivity 136–8, 142
laboratory data 299
P-glycoprotein 131, 132
pharmaceutical companies 139–41
pharmacodynamics 122–3, 133–8
pharmacokinetics 122–32
phase I drug metabolism 123–7
phase II drug metabolism 128–30
regulatory agencies 141–3
SLCO1B1 polymorphisms 131–2
sources of genetic variability 122–3, 134
statins 131–2
target identification 140
tests 143
thiopurine methyltransferase 128–9
UDP glucuronyl transferases 128, 130, 142–3
VKORC1 135
warfarin 126–7, 135
pharmacokinetics 54, 56–7
biotherapeutics 590, 596–7
clinical trials 242, 246, 247, 249, 268
herbal medicines 663–4
pharmacogenetics 122–32
toxicology 163, 170, 175, 177–8
pharmacological classifications of ADRs 32–53
A/B classification 32–4
allergic reactions 48–53
dose-relatedness of ADRs 33, 34–5, 42–4
DoTS classification 35, 38, 42–50
EIDOS classification 12, 35–42, 48–50
pharmacology testing 163, 242
pharmacotoxicology see toxicology
pharmacovigilance 1–25
adverse drug reactions 14–15
adverse effects and adverse reactions 11–12
adverse events 12–14
aims 3
benefit-to-harm balance 10–11
biotherapeutics 586
checklist for journals 705
CIOMS working groups 23, 25, 412–20
current challenges 416–18
data-mining techniques 25
definitions 1–3, 6–8
dictionaries 545–72
drivers of change 4–6
European Union directives 447–81
excipients 10
frequencies 20–1
herbal medicines 645, 651–2, 666–75
history 3–4
ICH guidelines 411–12, 418, 420–46
intensity 18–20
legal aspects 511–43
medicinal products 8–9
monitoring and surveillance 3, 21–2
oncology 636–8
pharmaceutical formulations 9–10
pharmacovigilance plans 390, 394–5, 407, 441–2, 458
regulatory aspects 411–509
reporting systems 18, 23, 25, 95–7
risk management strategies 390, 394–5, 407
seriousness 17–18
severity see intensity
signal 22–4
societal factors 573–84
susceptibility to ADRs 15–17
terminology 6–25
vaccines 603
website resources 685–97
Pharmacovigilance Working Party (PhVWP) 451–2, 460–2, 477, 531
pharmacy medicines 649
phases of drug development see clinical trials
phenacetin 124
phenelzine 55
phenobarbital 159
phenolphthalein 178–9
phenothiazines 79
phenotype testing 129
phenoxybenzamine 36
phenoxybenzylpenicillin 55
phenprocoumon 55
phenylbutazone 5
phenytoin 46, 54, 55, 124, 142, 159, 189
phosphate, inorganic 315–16
phototoxicity 243, 659, 662
physical examination 245
physical/physicochemical effects 40, 41
Physician Labeling Rule (PLR) 570
physiological effects 37, 46
physiologically based pharmacokinetics (PB-PK) 177–8
pioglitazone 160, 196
Piper methysticum see kava kava
INDEX

pituitary hormones 297
placebo-controlled trials 217, 228, 251–2, 429, 639
plasma calcium 315
platelets 330
pneumonia 50
point estimates 359
Poisson regressions 363–4
pokeroot (Phytolacca americana) 659
polyclonal products 592–3
polycythæmia 328
Polygonum multiflorum 661
polymorphonuclear leukocytes 329
polyoxyl castor oil 36
pooling of safety data 273–4, 364
poor metabolizers (PM) 124
porphobilinogen deaminase 134
porphyria 134
positive controls 59
post-approval drug safety 438–41, 576
post-authorization safety studies (PASS) 394–5, 457–8, 459, 476–80, 611–20
post-hepatic hyperbilirubinaemia 320
postmarketing drug safety 3
clinical trials 264–7
conditional periods 265
dosage changes 264–5
herbal medicines 656–7
investigator-sponsored studies 267
laboratory data 292
large simple studies 265–6
long-term safety studies 266
pharmacogenetics 141
regulatory aspects 487–8, 495, 500–505
risk management strategies 399–405
societal factors 575, 576, 581
toxicology 186–99
postmarketing reporting 62–3
postmarketing status changes 72
post-study events 428
post-treatment visits 221–3, 259–60
posture of patient/subject 296
potassium channels 133, 134
potassium-sparing diuretics 79
potential genotoxic impurities (PGI) 170
practolol 5, 80
pramipexole 49
prazosin 36
pre-analytical factors 294–300
pre-approval registration studies 252–64
adverse events 256–61
baseline characteristics 255–6
case follow-up 259–60
concurrent therapies 256, 261
controlled trials 254
data monitoring committees 261–2
end-points of clinical efficacy 256
general provisions 260–1
interim analyses 260, 263
laboratory data 292
named-patient use 264
patient selection/subgroups 254–5
study populations 271
trial design 255
unblinding 263
uncontrolled studies 261
vaccines 610–11
withdrawals 258–9
pre-authorization risk assessment 181
preclinical safety testing 236, 656, 663
prednisolone 55
preferred names/terms 217, 549, 552–3, 557–61, 563–7, 570
pregnancy see obstetrics
pre-hepatic hyperbilirubinaemia 320
prescribing
balanced 26–9
faults 26–39, 31
Prescribing Information (PI) 492
precription event monitoring (PEM) 23, 671–2, 675
prescription-only medicines (PoM) 649
prescriptions
errors/faults 27–9, 31
herbal medicines 649, 656
medication errors 26–7, 31
pharmacogenetics 121
risk management strategies 396–7
societal factors 582–3
statistical methods 375
presentation of safety data 271–80
adverse events 272, 275–8
checklist for journals 699–707
Clinical Study Reports 222, 271–3
clinical trials 355–6
common technical documents 275–7
data analysis 274–5, 278
incidence rates 278
laboratory data 339–44
observational studies 373–84
pooling of safety data 273–4
reporting in publications 279–80
summaries/executive summaries 275–7
see also statistical methods
pre-treatments 628–9
preventability 84–95
analysis without explicit criteria 84–5
assessment by consensus 84–5
assessment methods 84–95
categorization in explicit lists 84–5, 89
combination methods 84–5, 89–90
information technology 84–5, 88–9
mechanistic and clinical nature of ADRs 84, 90–7
medication errors 84–6
INDEX 727

medication-related factors 84–5, 87–8
standards of care 84–5, 86–7
toxicology 186
primaquine 134, 137, 144
prior beliefs 350–1
procainamide 128, 189
product liability 534–5
product licences of right (PLR) 648
product registration 650
progress reports 477–8
progressive multifocal leukoencephalopathy (PML) 397
proof-of-concept (POC) studies 170
propensity scores 381–2
Proportional Reporting Ratio (PRR) 25, 366–71, 385, 668
propranolol 80, 93
protective strategies 402–4
protein C 144
proteins 586–7
proteinuria 331
prothrombin time 321
pseudoallergic reactions 52
Psoralea corylifolia 662
psychological factors 30–1, 300
public health emergencies 472
public perceptions of vaccines 604–5
publication bias 384
Publishing Histories of Adverse Reactions to Medicaments (PHARMA) 700–2
pyrazinamide 144
pyridostigmine 134
pyrrolizidine alkaloids 659
QT interval 134, 240, 245
Qualified Person responsible for Pharmacovigilance (QPPV)
legal aspects 513, 516, 522–6
regulatory aspects 448–9, 453–6, 459, 470, 477
quality control 301–4, 665–6
quality of life (QoL) 225, 231, 232
quality testing 165
quantification of symptoms 229–33
quarterly reports 496
queen’s delight (Stillingia sylvatica) 659
questionnaires
clinical trials 221, 225–9, 232–3, 260
reporting systems 60–2
societal factors 579–80
radiotherapy 628, 635
randomized controlled trials (RCTs) 99
herbal medicines 672
statistical methods 351, 373
vaccines 610–11
randomized trials 355, 384
Rapid Alert (RA) 462
Rapid Cycle Analysis (RCA) 614–15
rapid reactions 45, 47
rare adverse reactions 397
rasburicase 144
rashes see cutaneous reactions
rate ratios 360, 363–4
reactive metabolite hypothesis 192–4, 197, 200–1
reactive oxygen species (ROS) 191
rebound phenomena 199, 222, 271
recall bias 376
receptor profiles 175
receptors 40
recombinant DNA technologies 587–8, 592
record linkage schemes 23
red blood cell (RBC) counts 327
red man syndrome 93
reduction reactions 123–7
Reference Member States (RMS) 460–2, 474, 531
reference ranges 304–7, 335–6, 345–6, 356
reference safety information 434
reference value changes (RVC) 341–2
refuted signals 23–4
Register of Chinese Herbal Medicine (RCHM) 671
regression analysis 338–9, 380–2
regulatory aspects
adverse drug reactions 411–12, 413–15
CIOMS guidelines 411–20
dictionaries 561–2
European Union directives 447–81
France regulations 483–4
Germany regulations 485–7
herbal medicines 648–55
Japan regulations 500–505
pharmacogenetics 141–3
pharmacovigilance 411–509
standardization and harmonization 412–47
United Kingdom regulations 481–2
USA regulations 487–500
relative risk (RR) 352–4, 358
relative systemic exposure 179–80
Remicade 184
remoxipride 6
renal function tests 309–14, 333–5
repeat-dose toxicity 161, 164, 216, 631
reporter identifiability 440
reporting odds ratio (ROR) 366, 368–70
reporting systems 59–64, 95–101
anecdotal reports in journals 100–1
checklist 699–707
CIOMS working groups 412–20
clinical trials 99, 218–21, 227–9, 256, 261–3, 277–80
combining evidence types 101
reporting systems (Continued)
European Union directives 447–8, 460–81
France regulations 483–5
frequencies of ADRs 69–72
general practice 59–60
Geroy regulations 485–7
herbal medicines 655, 656, 666–73
hospitals 60
ICH guidelines 418, 420–46, 464–5, 468–9, 474–5
improvements 64
Japan regulations 501–2, 504–5
media publicity 63–4
medication errors 31–2
national variations 62
nature of ADRs 64
observational studies 99
oncology 632–5, 640–1
personnel effects 63
pharmacovigilance 18, 23, 25, 95–7
reasons for failure to report 60–2
regulatory aspects 23, 412–47
societal factors 576–81
standardization and harmonization 412–47
statistical methods 351, 354, 365–73, 384–5
systematic reviews 97–9
time after marketing 62–3
under-reporting 59–60, 218–20, 354, 579, 669–70
United Kingdom regulations 481–2
USA regulations 489, 491–500
see also expedited reporting; spontaneous reporting
research product safety 538–41
residual confounding 375
resistance to treatment 631
respiratory disorders 52, 53
response to dechallenge 222, 258
responsiveness 35
restriction of studies 379
Reye’s syndrome 5
rhubarb (Rheum officinale) 659
rifampicin 54, 144
risk assessment
allometry 176–8
biological and biotechnological drugs 182–6
biotherapeutics 589–90, 593–4
definition 10–11
frequencies of ADRs 20–1, 75–7
herbal medicines 668–9
legal aspects 541
minimizing risks 395–7, 458–60
NOAEL, with conventional dosimetry 178–9
NOAEL and relative systemic exposure 179–80
perception of risk 77–8
pharmacological classifications 45, 47–8
pre-authorization 181
predictive ability of non-clinical studies 181–6
small-molecule drugs 181–2
societal factors 581
statistical methods 352–4
susceptibility to ADRs 15–17
toxicology 174–86
risk difference 357–9
risk evaluation and mitigation strategies (REMS) 265, 398–9, 406, 499
risk management plans (RMP) 390–2, 397, 405–6, 456–60, 474, 480, 561, 638, 639
risk management strategies 389–409
benefit-to-harm balance 391–2, 399, 402
clinical data 393–4
clinical trials 238–9, 275
definition and general principles 390–1
future challenges 405–6
minimizing risks 395–7, 458–60
monitoring 400–2
non-clinical data 392–3
oncology 638, 641
pharmacovigilance plans 390, 394–5, 407
postmarketing drug safety 399–405
protective strategies 402–4
regulatory aspects 420, 456–60, 474, 480
safety specifications 391–4
special challenges 397–8
susceptibility 399–401
risk ratios (RR) 75–6, 357–9
Rituxan 183
rituximab 183
rivastigmine 159
rofecoxib 6, 389–90
rosemary (Rosmarinus officinalis) 659
rosiglitazone 6, 160, 196, 390
Roussel Uclaf Causality Assessment Method (RUCAM) 668
rule-based errors 30–1
Ruvuna formula 337–8
ryanodine receptors 134
RYR1 gene 134
SAFETEE general inquiry questionnaire 230
safety biomarkers 237–8
safety management teams 238
safety pharmacology testing 161, 165–6
safety profiles 215, 262, 267–71, 281
data collection reassessment 271
investigator’s brochures 267
laboratory data 334
patient numbers 271
patient subgroups 268–70
risk management strategies 398
withdrawal and dependence phenomena 270–1
safety signals 416, 419–20
INDEX

safety specifications 391–4
safrole 659
Sage (Salvia officinalis) 659
St John’s wort (Hypericum perforatum) 54, 55, 648, 651, 657, 662–4
salicylates 191
salvarsan 5
sample size 352
sampling strategies 300–1
sanctions 526–8
saponins 659
sarsaparilla (Smilax regelii) 659
sassafras (Sassafras albidum) 659
scaling of toxicity data 177–81
SCN5A gene 134
scope of studies 175
seasonal variations 296–8
selective serotonin reuptake inhibitors (SSRIs) 55, 125, 270–1
self-administered questionnaires 227–8
self-controlled case series (SCCS) method 617–18
Senecio spp. 658
senna (Senna alexandrina) 659
sequelae 35–6, 42
sequence numbers 549
sequential probability ratio tests (SPRT) 371–3, 385
serious adverse events
clinical trials 221–3, 256, 266, 277
definitions 424–5, 490
regulatory aspects 427, 440, 450, 464–7, 469–70
societal factors 575
statistical methods 367–8
sertindole 6, 133
serum cystatin C 311–12
serum sickness 188, 594
sesquiterpene lactones 659
seven deadly sins 61
severity see intensity
Shankhapushpi 55
shift tables 341, 343
short-term follow-up 221–2, 259–60, 352
Siberian ginseng (Eleutherococcus senticosus) 55
sibutramine 394–5
sildenafil 44
simvastatin 131
single ascending dose (SAD) 243
single nucleotide polymorphisms (SNP) 122
skin reactions 52, 197–8
SLCO1B1 gene 93, 131–2
smallest significant difference (SSD) 307
smoking 248, 300
societal factors 573–84
disembedding mechanisms 573–4
epidemiology of ADRs 574–5
information about ADRs 581–3
reporting systems 576–81
social production of ADRs 576–9
trust 579–81
sodium bicarbonate 36, 54
sodium channels 134
solicited reports 439, 495
sotalol 6, 80, 134
species selection 172, 175
species susceptibility 181
specific monitoring 237, 252
spironolactone 5, 37, 55
sponsor obligations 444, 464–5, 539
spontaneous reporting 99–100, 227–9
herbal medicines 666–8, 669–70
societal factors 581
statistical methods 351, 365–73, 384–5
sports anaemia 299
SSRIs see selective serotonin reuptake inhibitors
stability 301
standard operating procedures (SOP) 520, 523
standard product information 570–1
standard questions 224–5, 227–9, 280–1
Standardized MedDRA Queries (SMQ) 459, 474, 565
standards of care 84–5, 86–7
statins 79, 131–2, 382–3, 389
statistic of disproportionate reporting (SDR) 25
statistical methods 349–88
adverse drug reactions 351, 352–5, 360, 364–7, 384
adverse events 351, 352–5, 356–4
analysis and presentation of data 355–6, 373–84
background and context 349–50
Bayesian confidence propagation neural network (BCPNN) 367–70
clinical trials 272, 352–6, 364–5
confounding 374–82
DuMouchel method 370–1
duration of follow-up 352
efficacy trials 352–5
frequentist disproportionality methods 365–9
gamma Poisson shriners 370–1
hierarchies of evidence 351
information bias 374, 385
laboratory data 338–44, 354
meta-analyses 354–5, 383–4
multiple tests 354–5
observational studies 351, 373–84, 385
prior beliefs 350–1
randomized trials 355, 384
relative risk of adverse events 352–4
safety assessment during drug development 350
sample size 352
sequential probability ratio tests 371–3
spontaneous reporting 351, 365–73, 384–5
surrogate markers 355–6
time-based measures 360–4
toxicology 172
under-reporting 354
INDEX

730

statins 79, 93
stavudine 191
stereochemistry 180
Stevens–Johnson’s syndrome (SJS) 137, 138, 404
stimulated reporting 438
stratification 379–80
stress 300
strict liability 535–6
structural tests 162
Structured Product Labeling (SPL) 570–1
structured summaries 702–3
study design 175, 375–9
study populations
  clinical trials 247–8, 254–5, 268–71, 273–4
  risk management strategies 394
  statistical methods 384
Stufenplanbeauftragter 485
Stufenplanverfahren 485
subjective symptoms 228, 236–7
substance abuse 298
sucinylcholine see suxamethonium
sulfanilamide 4–5
sulfasalazine 65
sulfonamides 128, 132, 134, 137, 189, 404
sulindac 36
sumatriptan 81
Summaries of Product Characteristics (SmPCs) 395–6, 557, 583
Summary of Clinical Safety 276
summary tabulations 435–6, 497
superoxide dismutases (SOD) 192
suprofen 5
surgical interventions 18
surrogate markers 355–6
surveillance 3, 21–3, 603–24
surveys 69–72, 73
susceptibility
  biotherapeutics 592–4
  clinical trials 216, 278
  cutaneous reactions 197–8
  drug reactive metabolite hypothesis 192–4, 197, 200–1
  future developments 198–9
  gender effects 198
  glucuronidation 198
  hepatotoxicity 195–7
  immune-mediated effects 194–5, 201
  mitochondrial toxicity 190–2
  oncology 627–8
  pharmacogenetics 121, 133
  pharmacological classifications 42–4, 46, 48
  pharmacovigilance 15–17
  preventability 91, 93–5
  risk management strategies 399–401
  risk perception 77
  toxicology 181, 188–99, 200–1
suspected unexpected serious adverse reactions (SUSARs) 450, 464–7, 469–70, 481, 490, 561
suxamethonium (succinylcholine) 46, 128, 134
symptomatic adverse events 223–9, 257
system-organ classes (SOC) 217, 437–8, 552–3, 558, 560–1, 564–8, 570
systematic reviews 97–9, 639, 672–3
Systematized Nomenclature of Medicine (SNOMED) 568–70
T cells 194–5, 595
tacrine 128, 159, 195
tacrolimus 131
tamarind (Tamarindus indica) 55
tansy (Tanacetum vulgare) 659
tardive dyskinesia 134
target identification 140
targeted medical events 25
telemetry 243
teleoanalysis 101
telopeptides 316
temafloxacin 5, 227–8
tenozolamide 627
tenofovir 131
teratogenicity 5, 199, 270, 396–7, 402, 403, 405
terfenadine 6, 54, 92, 133
terodiline 5
test doses 34
tetracyclines 36, 54, 55, 92, 191
tetradodothyronine 324
TGN1412 monoclonal antibody 6, 249–51
Thai 137
thalidomide 4–5, 45, 396, 402, 403, 405
The Health Improvement Network (THIN) 23
theophylline 55
Therapeutic Goods Administration (TGA) 652–3, 661
Therapeutic Substances Act 1925 5
thiazide diuretics 55
thiazolidinediones 160, 195–6
thioguanine 128
thionamides 50
thiopurine methyltransferase (TPMT) 93, 128–9, 144
deficiency 403
gene 142
thioridazine 133, 134
third party administration 495
thrombocytes 330
thrombocytopenia 134, 241
thyroid function 324–5, 334
ticarcillin 36
ticlopidine 54
time-based measures 360–4
time-event analyses 278
time-relatedness of ADRs 43–5, 47–8, 91, 93, 199
timolol 80
tissue antigens 607
INDEX

731

tissue damage 65
tissue proteins 41
titles 700, 702
TNM classification system 629–30
tocaainide 5
tolbutamide 124, 189
tolcapone 6, 128, 197
tolerability 216, 242, 247
torsade de pointes 133, 134, 404
total protein counts 320, 338
toxic epidermal necrolysis (TEN) 137, 138
toxic potential 162–4
toxic reactions 187, 188–9
toxicity 42, 44, 94
toxicity testing 157–68, 200
toxicity to reproduction testing 162
toxicokinetic monitoring 158, 163–4
toxicology 157–214

adverse drug reactions 186–99
allometry 176–8
animal welfare 160–2
biological and biotechnological drugs 164–7, 182–6
clinical trials 158, 169, 171
data interpretation and risk assessment 174–86
documentation 167–8
dose-response relationships 164, 175, 178–9, 187–99
drug discovery and development 168–74
drug examples 199–200
extrapolation to humans 176–81
future developments 198–9

good laboratory practice 158–62
hypersusceptibility 188, 189–99, 200–1
international and regional guidelines 164
NOAEL with conventional dosimetry 178–9
NOAEL and relative systemic exposure 179–80
non-clinical testing 161–3, 165, 172–6, 181–2
postmarketing drug safety 186–99
pre-authorization risk assessment 181
predictive ability 181–6
time-relatedness of ADRs 199
toxic potential 162–4
toxicity testing 157–68, 200
withdrawn drugs 186–7
toxicophores 192–4
toxicoproteomics 199
TPMT see thiopurine methyltransferase
traditional Chinese medicine (TCM) 647, 650, 652, 657–8, 661–2, 665–6
training 455
tranexamic acid 37
translations 563
trastuzumab 183, 627
treatment-emergent signs and symptoms (TESS) 13, 220–1, 255–6

trial protocols 253, 254, 257, 355
triamterene 37, 65
triazolam 5
tricyclic antidepressants 44, 55, 94, 125
triglycerides 297, 322–4
triiodothyronine 324
troglitazone 6, 37, 128, 195–6, 390
trust 579–81
tryptophan 5, 36, 92
tuberculosis 629–30
tumor lysis syndrome (TLS) 592
two-by-two tables 357
type I reactions see anaphylaxis
type II reactions see cytotoxic reactions
type III reactions see immune-complex reactions
type IV reactions see cell-mediated reactions
Tysabri 184
UDP-glucuronosyltransferase (UGT) 128, 130, 142–3, 196, 198
UGT1A1 gene 142, 144
ultrarapid metabolizers (UM) 124
UMC see Uppsala Monitoring Centre
unblinding 263
uncontrolled studies 261, 280–1
under-reporting 59–60, 218–20, 354, 579, 669–70
unexpected adverse events/reactions 425–7, 440, 450, 464–7, 469–70, 484–5, 486, 490, 491–2, 494–500, 502, 504
United Kingdom (UK) regulations 481–2, 523, 648–52, 667–8
United States of America (USA) regulations
FDA Amendments Act 2007 499–500
herbal medicines 654
investigational new drugs 487, 491–4
legal and regulatory framework 487–8
marketed products 494–9
pharmacovigilance 487–500
reporting systems 489, 491–9
see also Food and Drug Administration
unlabelled adverse events 490, 503
unlicensed herbal medicines 648–9
unlicensed indications 80–2
unlicensed uses 631
unlisted adverse events 426
unsolicited reports 23
unverified signals 23–4
upper limit of reference ranges (ULRR) 321
Uppsala Monitoring Centre (UMC) 551–2, 562
herbal medicines 660, 667, 669–71, 675
website resources 692–3
Urabe mumps vaccine 608, 609–11, 619
urea 309–10
uric acid/urate 311
uridyl diphosphate glucuronyl transferase (UDGT) 319
urinalysis 331–3, 334
INDEX

urinary microalbumin 312–13
urinary N-acetyl-β-D-glucosaminidase (NAG) 312
urinary tract infections (UTI) 332
urobilinogen 332
use restrictions 4–6

Vaccine Adverse Event Reporting System (VAERS) 498–9, 612–13
Vaccine Safety Datalink (VSD) 614–15
vaccines 398
active surveillance systems 614–15
causality assessment 604, 608–10, 615
definitions 603
direct pathogenesis 605
ecological studies 619
epidemiology 610–11, 615–18
immune-mediated effects 606–7
oncology 627
passive surveillance systems 612–13
pathogenesis 605–7
pharmacological classifications 35
post-authorization safety studies 611–20
pre-approval registration studies 610–11
public perceptions 604–5
risk management strategies 394, 397–8
safety surveillance 603–24
special characteristics 604–5
Vaccinium macrocarpon 664–5
valproate 191
vancomycin 45, 93
Vectibix 183
verified signals 23–4
very low density lipoprotein (VLDL) 322–4
vigabatrin 50
vinca alkaloids 25, 36
Virtual Central Laboratory (VCL) 337
visual analogue scales (VAS) 230–1
visual field loss 50
vital signs 216, 245
vitamin K epoxide reductase enzyme complex subunit 1 (VKORC1) 127, 135–6
VKORC1 gene 134, 142, 144
voluntary withdrawals 651
warfarin 59, 124, 126–7, 134, 135–6, 142, 144, 189, 404, 656, 664–5
website resources
institutional websites 689–97
national pharmacovigilance websites 685–9
weight gain 135
white blood cells 328–30
WHO-UMC causality algorithm 66–7
wild carrot (Daucus carota) 659
withdrawal phenomena
clinical trials 221–2, 241, 258–9, 270–1, 277
pharmacological classifications 45, 48
toxicology 199
withdrawn drugs 4–6
herbal medicines 651
risk management strategies 389–90, 405
toxicology 186–7
Women’s Health Initiative (WHI) 358–63
World Health Organization (WHO)
definitions 1–2, 14, 43
dictionaries 547–50, 551–3, 568, 693
drug class 78
herbal medicines 645, 647
regulatory aspects 472
reporting systems 100
statistical methods 369–70
toxicology 164, 179
vaccines 604, 612, 620
website resources 688–9, 692
see also Council for International Organizations of Medical Sciences; International Conference on Harmonization; Uppsala Monitoring Centre
worldwide market authorization status 434
Xaio chai hu tang (sho-salko-to) 55
xamoterol 5
yarrow (Achillea millefolium) 659
Yellow Card scheme 23, 99–100
herbal medicines 667–8, 671
oncology 637
regulatory aspects 482
societal factors 578–9
statistical methods 365
vaccines 612–13
yellow dock (Rumex crispus) 659
yohimbine (Pausinystalia yohimbe) 55
zidovudine 191
zimeldine 5
zomepirac 5